BofA raises HCA Healthcare stock price target on solid execution
BofA Securities raised its price target on HCA Healthcare (NYSE:HCA) to $500 from $450, citing solid execution and upside from supplemental Medicaid programs. The company's Q3 EBITDA exceeded estimates, with revenue of $19.85B and EPS of $7.22. HCA maintained its guidance range but faces near-term headwinds. The stock trades at an EV/EBITDA of 9.6x and a P/E ratio of 14.85.
How this was made
The 30-second read
Why it matters
Analyst target raise adds a bullish catalyst, but mixed outlook on 2027 earnings and payer‑mix risks may limit price appreciation.
Market read
The new target could attract short‑term buying interest, while underlying earnings quality remains a key watch.
What to watch
Uninsured volume rise and a $400 million EBITDA hit from payer‑mix changes could temper upside.
Background
BofA's upgrade follows HCA's Q3 2026 earnings beat, with adjusted EPS of $7.22 versus $6.65 consensus and revenue of $19.85 bn.
Ticker impact
BofA Securities raised its price target for HCA Healthcare to $500, citing higher EBITDA multiple and supplemental Medicaid program upside.
likely upward pressure as investors price in the higher target and Medicaid program benefits
The new $500 target reflects a 10.5x 2027 EBITDA multiple, a material increase over the prior 9.8x, indicating BofA sees stronger earnings potential.
Market effects
The target raise may lift other hospital operators as Medicaid program expectations improve.
U.S. healthcare sector could see modest gains.
Limited to U.S. equities; no broader macro impact.
Counterpoint
The target increase may be premature given lingering payer‑mix headwinds and potential Medicaid cuts.
Key entities
- analystBofA Securities
Raised price target to $500, maintaining Neutral rating.
- companyHCA Healthcare Inc
U.S. hospital operator reporting Q3 results.
